The FDA approved Zinbryta (daclizumab), a new once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS), Biogen and...
Biogen Idec and AbbVie announced the full results from the Phase III DECIDE clinical trial, which show Zinbryta (daclizumab high-yield...
The FDA has accepted for review the companies� Biologics License Application (BLA) requesting marketing approval of Zinbryta (daclizumab high-yield process),...
Biogen and AbbVie announced the voluntary worldwide withdrawal of Zinbryta for relapsing multiple sclerosis. The companies believe that characterizing the...
The National Institute for Health and Care Excellence (NICE) has published a final appraisal determination recommending Zinbryta (daclizumab high-yield process)...
The European Commission (EC) has granted marketing authorization for Zinbryta (daclizumab) for the treatment of adult patients with relapsing forms...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion...
Full results from the Phase III DECIDE study published this week in the New England Journal of Medicine (NEJM), as...